Kinzalmono

Telmisartan, the active ingredient in Kinzalmono, is an Angiotensin II receptor blocker presented as an oral tablet for oral administration. It is indicated for the treatment of hypertension and for lowering cardiovascular risk in adult patients, including those with associated comorbidities.

GNH USA supplies Kinzalmono as a licensed, Good Distribution Practice‑compliant pharmaceutical product to hospitals, pharmacies and clinics worldwide, providing reliable international sourcing for qualified healthcare providers. The product conforms to European Union regulatory standards and is available for export under controlled quality agreements.

Telmisartan, an angiotensin II receptor blocker, is used to manage conditions related to the renin‑angiotensin system. - Hypertension: lowers blood pressure and reduces the risk of stroke and heart attack. - Cardiovascular risk reduction: decreases incidence of major cardiovascular events in high‑risk patients. - Left ventricular hypertrophy: slows progression of cardiac remodeling associated with high blood pressure.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Upper respiratory tract infection: symptoms such as nasal congestion or sore throat.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Hyperkalemia: elevated potassium levels that can cause cardiac arrhythmias. - Renal impairment: worsening kidney function, indicated by increased serum creatinine. - Hepatic injury: signs of liver damage such as jaundice or elevated liver enzymes.

Before initiating therapy, consider the following precautions: - Renal function monitoring: assess serum creatinine and eGFR periodically. - Serum potassium monitoring: check potassium levels, especially when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity. - Breastfeeding: avoid use while nursing as the drug may be excreted in milk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Telmisartan may interact with several medicines; review the following: Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal impairment. - Potassium‑sparing diuretics or potassium supplements: heightened risk of hyperkalemia. - ACE inhibitors or other ARBs: additive blood‑pressure lowering effect and potential renal dysfunction.

Moderate Interactions (Monitor Closely): - NSAIDs: may diminish antihypertensive effect and affect renal function. - Lithium: can raise lithium concentrations, increasing toxicity risk. - Rifampin: may lower telmisartan plasma levels, reducing therapeutic efficacy.